Kymera Therapeutics' Q2 2025 earnings call highlights clinical progress, Gilead and Sanofi partnerships, and financial strength, setting a strong stage ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

Source: Analyst estimates for the quarter provided by FactSet.

Currently exempt from US tariffs, pharmaceutical manufacturers fear steep surcharges, as promised by the US president on ...

Kymera Therapeutics, Inc. (($KYMR)) has held its Q2 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported ...

Privately-held dermatology specialist LEO Pharma today revealed robust growth and significantly improved profitability, ...